Proton arc therapy lowers modeled circulating blood dose by 14% versus IMPT
In ten head and neck cancer plans, proton arc therapy reduced simulated mean circulating blood dose from 0.563 to 0.483 Gy(RBE).
In ten head and neck cancer plans, proton arc therapy reduced simulated mean circulating blood dose from 0.563 to 0.483 Gy(RBE).
A two-variable NTCP model predicted grade ≥2 acute esophageal toxicity with AUC 0.75 and was incorporated into Dutch proton selection criteria.
After 70 Gy(RBE) in 28 fractions, ten-year biochemical control was 78.5%, with grade ≥3 GI and GU toxicity in 5.2% and 3.1%.
Across six European centers, CT-based stopping-power estimates varied by approximately 1% in soft tissue and up to 4.6% in compact bone.
Two weeks after proton FLASH, normal tongue tissue retained more triglycerides and showed distinct lipid-remodeling responses compared with conventional irradiation.
A microdosimetry-based proton prescription model produced target-averaged RBE values of 1.08–1.18 while revealing substantially higher biological effectiveness near distal beam edges.
Removing lateral setup-shift scenarios reduced optimization time by 24 minutes across 16 prostate proton plans without significant changes in dosimetry or robust coverage.
Direct AI-generated IMPT spot weights achieved over 98% whole-body gamma agreement for prostate and brain plans, but lung target coverage deteriorated.
In 40 breast and chest wall plans, DynamicArc improved coverage and robustness in challenging anatomies but increased thyroid dose and hotspots.
At 15 years, in-field second malignancy incidence was 0% after proton RT versus 11.1% after photons in 108 retinoblastoma patients.
A nonclinical time-driven PBS configuration delivered 25 Gy in approximately 0.6 seconds at 42 Gy/s while preserving proton range and scanning accuracy.
Three representative liver cases illustrate breath-hold IMPT, compression-based proton SBRT and spatially fractionated proton therapy with detailed planning and QA workflows.
Radiation-induced MRI enhancement occurred in 7.9% of children after proton therapy and spatially overlapped with elevated LET-associated biological dose.
ADoTA achieved over 99% beamlet-level gamma agreement and rapid proton plan reconstruction but systematically underestimated target D98.
A head-and-neck-trained diffusion transformer generalized proton dose denoising across three unseen sites, but optimized Gaussian filtering matched or outperformed several global metrics.